OxySure Systems (OXYS) Receives Commercial Drone Approval from FAA
Frisco, Texas, September 1, 2015 – OxySure Systems, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its “oxygen from powder” technology and other medical solutions, today announced that the Company’s petition for exemption for commercial drone usage was granted by the Federal Aviation Administration (FAA), a division of the United States Department of Transportation (DOT).
On June 1, 2015 the Company submitted a petition to DOT seeking an exemption from the applicable Federal Aviation Regulations (FARs) in order to allow for the operation of small Unmanned Aircraft Systems (sUAS) under certain conditions and limitations. The purpose of the petition involves aerial operations in support of emergency response and services, disaster response and recovery, search and rescue, and humanitarian relief efforts.
The granted exemption permits the operation of small, unmanned sUASs (commonly known as drones) under controlled conditions in airspace that (1) is limited, (2) is predetermined, and (3) would provide safety enhancements to First Responders on the front lines in our communities. Other highly effective uses of sUAS endeavors include response to humanitarian relief efforts, emergency and disaster response, and Search & Rescue (SAR) operations. Providing a clear visual from a low altitude flight is extremely valuable with respect to emergency/medical response and SAR missions. Low altitude real-time imagery assists with locating people, locating emergency situations, delivering much-needed emergency supplies quickly as an easily detachable payload (including medical emergency supplies), recognizing and identifying critically affected areas, locating safety zones and increasing situational awareness of identified risks and hazards, resulting in more efficient, decisive and effective response plans. Such planning assists to minimize reaction time and increase the probability of the best outcome for the situation – without increasing risk to human lives and property.
OxySure plans to provide drone solutions to a wide array of first response customers nationwide, including fire departments, paramedics, first responders, and the military. These solutions will include drone products designed to carry much-needed medical and emergency medical payloads such as Automated External Defibrillators (AEDs), oxygen, first aid supplies, water, food, safety gear and other lifesaving equipment and supplies. Related services will include assistance with exemption petitions, training, drone servicing and maintenance and parts supply.
“We are very pleased that the FAA has granted our exemption petition,” said Mr. Julian Ross, President and CEO of OxySure. “This is yet another significant step towards our goal of improving medical and emergency outcomes by “bridging the gap” – meaning, bridging the gap between the onset of a medical or life-threatening emergency and the time that first responders arrive on the scene or assistance becomes otherwise available.”
A copy of the FAA exemption decision can be found here:
The FAA provides limitations on commercial drone usage, including the following:
- Payloads cannot exceed 55 pounds, including the weight of the drone;
- The drones may not be operated at speeds exceeding 87 knots (100 miles per hour);
- Drones must be operated at an altitude of no more than 400 feet above ground level (AGL); and
- Drones may not operate within 5 nautical miles of an airport.
About OxySure Systems, Inc.
OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. www.OxySure.com
Forward-Looking Statements
Statements in this earnings release that are not historical facts are considered to be forward-looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward-looking statements are subject to risks and uncertainties, many of which are beyond management’s control and actual results and performance may differ significantly from those contained in forward-looking statements. OxySure Systems, Inc. intends any forward-looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said safe harbor provisions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. OxySure Systems, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements is included in OxySure Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2014.
Contacts:
Renmark Financial Communications, Inc.
Bettina Filippone: bfilippone@renmarkfinancial.com
Tel.: (416) 644-2020 or (514) 939-3989
Redchip Companies, Inc.
Jon Cunningham: jon@redchip.com
800-733-2447, ext. 107
Tags: